Align Technology (ALGN)
(Delayed Data from NSDQ)
$212.15 USD
+1.37 (0.65%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $211.69 -0.46 (-0.22%) 7:58 PM ET
4-Sell of 5 4
C Value B Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$212.15 USD
+1.37 (0.65%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $211.69 -0.46 (-0.22%) 7:58 PM ET
4-Sell of 5 4
C Value B Growth C Momentum C VGM
Zacks News
Why Brookdale Senior Living (BKD) Could Be Positioned for a Slump
by Zacks Equity Research
One stock that you may want to consider dropping is Brookdale Senior Living Inc. (BKD), which has witnessed a significant price decline in the past four weeks.
AmerisourceBergen's PharMEDium Slows Down, Competition Rife
by Zacks Equity Research
AmerisourceBergen Corporation (ABC) is facing immediate integration risks from its acquisition of PharMEDium. Also, competition in the generic space raise concern.
STAAR Surgical (STAA) Catches Eye: Stock Moves 8.3% Higher
by Zacks Equity Research
STAAR Surgical Company (STAA) moved big last session, as its shares jumped over 8% on the day.
Zacks.com featured highlights: Gray Television, Align Technology, SolarEdge Technologies, Nova Measuring Instruments and Brooks Automation
by Zacks Equity Research
Zacks.com featured highlights: Gray Television, Align Technology, SolarEdge Technologies, Nova Measuring Instruments and Brooks Automation
BioScrip (BIOS) Gains on CORE Initiatives, Competition Rife
by Zacks Equity Research
The company achieved annualized supply chain improvement since the acquisition of Home Solutions.
OPKO Health (OPK) Posts Narrower-than-Estimated Loss in Q2
by Zacks Equity Research
OPKO Health (OPK) posted lackluster Q2 numbers due to rising operating expenses owing to investment associated to the launch of RAYALDEE, and consistent investment in the pharmaceutical pipeline.
The $200 Club: Will Facebook Beat Alibaba There First?
by Kevin Cook
When you find great fundamental growth stories that institutions must own, you can buy and trade them for a long time in a bull market.
CVS Health Grows on Specialty Pharmacy amid Retail Woes
by Zacks Equity Research
CVS Health (CVS) rides on strong PBM selling season. Poor Retail/ LTC business and escalating expenses are drag on the bottom line.
Chimerix (CMRX) Q2 Loss Narrower than Expected, Revenues Down
by Zacks Equity Research
Chimerix (CMRX) revenues in Q2 were hurt by reduced reimbursable expenses related to the company's BARDA developmental contract.
Haemonetics Banks on Solid Plasma & Haemonetics Management
by Zacks Equity Research
Despite encouraging growth at the Plasma and Haemonetics Management franchises, the underperformance at the BloodCenter franchisee was quite a dampener for Haemonetics (HAE).
Bio-Techne (TECH) Beats Earnings, Revenue Estimates in Q4
by Zacks Equity Research
Bio-Techne (TECH) rides high on strength in all three segments in Q4. Also, the company is focusing on product innovation through research and development.
Nevro's (NVRO) Q2 Loss Wider than Expected, Revenues Beat
by Zacks Equity Research
Nevro's (NVRO) topline gains on continued global adoption of HF10 therapy. Rising operating expenses are major concerns.
Focus on These 5 Top-Ranked Profitable Stocks in August
by Zacks Equity Research
Higher net income ratio usually implies a company's ability to generate ample revenue and successfully manage all its business functions.
STERIS (STE) Beats on Q1 Earnings & Revenues, Margins Up
by Zacks Equity Research
STERIS' (STE) organic growth performance was strong across most segments in Q1. Robust cash position was another upside.
BioScrip (BIOS) Q2 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
BioScrip (BIOS) continues to disappoint in Q2 mainly due to its strategic shift to focus on growing its core revenue mix.
BioTelemetry (BEAT) Q2 Earnings Top, Revenues Meet Estimates
by Zacks Equity Research
BioTelemetry (BEAT) rides high on all its segments in Q2. The company is also putting in efforts in product innovation through research and development.
Myriad Genetics (MYGN) Beats on Q4 Earnings & Revenues
by Zacks Equity Research
Myriad Genetics (MYGN) rides high on strength in Molecular diagnostics with significant contributions from GeneSight. Also, hereditary cancer testing continues to witness sequential growth.
Penumbra (PEN) Loss Meets Estimates, Revenues Beat in Q2
by Zacks Equity Research
Penumbra (PEN) witnessed strong growth across all its geographies and product lines in Q2. New product launches raise hope.
CVS Health (CVS) Q2 Earnings Beat, '17 Guidance Narrowed
by Zacks Equity Research
CVS Health continues to grow (CVS) with Pharmacy Services business. However, its Retail/LTC sales drop.
Henry Schein (HSIC) Q2 Earnings & Revenues Beat, View Intact
by Zacks Equity Research
Henry Schein (HSIC) maintained its stellar performance in Q2 as well, courtesy of strength in all of its business segments.
Orthofix (OFIX) Earnings Meet, Sales Beat Estimates in Q2
by Zacks Equity Research
Orthofix (OFIX) rides high on strength in Biologics and Spine Fixation businesses. Moreover, raised full-year 2017 guidance buoys optimism.
Haemonetics (HAE) Q1 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Haemonetics (HAE) rides high on Plasma and Haemonetics Management franchises strength in Q1.
Bio-Rad (BIO) Misses Q2 Earnings & Sales, Margin Declines
by Zacks Equity Research
Bio-Rad's (BIO) sales declined on ERP-related disruption. Margin pressure continues.
Cardiovascular Systems Rides on Innovation Amid Several Woes
by Zacks Equity Research
Cardiovascular Systems' (CSII) low operating expenses and strong revenue performance contributed to the upside in Q2 earnings.
Pacific Biosciences (PACB) Posts Wider-than-Expected Q2 Loss
by Zacks Equity Research
Pacific Biosciences (PACB) posted a dull quarter with revenues declining in Q2. However, the company continues to anticipate 35% to 45% growth in product and service revenues for the year.